The m7GpppN cap at the 5′ end of eukaryotic mRNAs is important for transcript stability and translation. Three enzymatic activities that generate the mRNA cap include an RNA 5′-triphosphatase, an RNA guanylyltransferase, and an RNA (guanine-7-) -methyltransferase. The physical organization of the genes encoding these enzymes differs between mammalian cells and yeast, fungi, or viruses. The catalytic mechanism used by the RNA triphosphatases of mammalian cells also differs from that used by the yeast, fungal, or viral enzymes. These structural and functional differences suggest that inhibitors of mRNA capping might be useful antifungal or antiviral agents. The authors describe several whole-cell yeast-based assays developed to identify and characterize inhibitors of fungal mRNA capping. They also report the identification and characterization of the natural product sinefungin in the assays. Their characterization of this S-adenosylmethionine analog suggests that it inhibits mRNA cap methyltransferases and exhibits approximately 5-to 10-fold specificity for the yeast ABD1 and fungal CCM1 enzymes over the human Hcm1 enzyme expressed in yeast cells. (Journal of Biomolecular Screening 2005:355-364) 
INTRODUCTION
M ETHYLATION AND CAPPING of the 5′ ends of elongating mRNAs are important steps for efficient expression of eukaryotic genes. 1 Shortly after initiating transcription, the 5′ ends of nascent eukaryotic mRNAs are capped with a 7′-methyl-GTP residue that protects the elongating RNA from digestion by 5′ exonucleases. 2 Once transcription is complete, a polyadenylated tail is added to the 3′ end of the transcript. It is at this point that the mature mRNA moves from the nucleus to the cytoplasm for translation. Three enzymatic reactions synthesize and attach the m7GpppN cap. 3 The first reaction involves an RNA 5′triphosphatase, which hydrolyzes the 5′-triphosphate of the nascent RNA to form a diphosphorylated nucleotide end (ppN). The second enzyme, an RNA guanylyltransferase, adds GMP to cap the 5′ ppN of the mRNA. The final step is catalyzed by an RNA (guanine-7-)-methyltransferase, which transfers a methyl group from S-adenosylmethionine (AdoMet) to the N-7 position of the GpppN end of the nascent mRNA to produce a m7GpppN terminated RNA and S-adenosylhomocysteine (AdoHyc).
The physical organization of the mRNA capping enzymes and the genes that encode them differs significantly between mammalian cells, fungi, and eukaryotic viruses. 3 In Saccharomyces cerevisiae, the RNA 5′-triphosphatase, the RNA guanylyltransferase, and the RNA (guanine-7-)-methyltransferase enzymes are encoded by the CET1, CEG1, and ABD1 genes, respectively. [4] [5] [6] [7] Genes that encode homologs of Cet1p, Ceg1p, and Abd1p have been isolated from other yeast and fungi, including the fission yeast Schizosaccharomyces pombe (PCT1, PCE1, PCM1) [8] [9] [10] and the pathogenic fungus Candida albicans (CaCET1, CGT1, CCM1). 8, 11, 12 Although the yeast and fungal genes express separate triphosphatase and guanylyltransferase enzymes that associate to form a heterodimeric complex, mammalian cells express a single polypeptide, MCE1p, 13, 14 which encodes both of these enzymatic activities. The methyltransferase of mammalian cells (Hcm1p) is a monomeric enzyme encoded by the HCM1 gene. 8 There is also considerable variation in the organization of the capping enzymes expressed by eukaryotic viruses. 3, 15 In addition to differences in the organization of mRNA capping enzymes, the catalytic mechanisms of the yeast, fungal, and viral RNA triphosphatases differ from the mechanism used by the mammalian RNA triphosphatases. The yeast, fungal, and viral en-zymes have divalent cation-dependent activity and contain 3 conserved motifs required for catalytic activity. [16] [17] [18] In contrast, the mammalian RNA triphosphatases contain a tyrosine protein phosphatase motif with an active-site cysteine and a conserved proximal aspartic acid. 19 Reactions catalyzed by the mammalian enzymes involve a cysteinyl phosphate intermediate that does not require a divalent cation cofactor.
The physical and functional differences between the mammalian capping enzymes and the enzymes from fungi, protozoa, and viruses suggest that the capping enzymes of these pathogens are potential targets for novel antifungal, antiprotozoal, or antiviral agents. 3 Schwer et al. 20 demonstrated that the essential yeast capping genes (CET1, CEG1, and ABD1) could be replaced with the C. albicans homologs (CaCET1, CGT1, and CCM1). Similarly, yeast mutants lacking the 3 mRNA capping genes can be complemented in vivo by the mammalian MCE1 and HCM1 genes. 8 When 1 or more of the 3 S. cerevisiae mRNA capping genes are deleted and replaced by plasmid-borne genes from C. albicans or Homo sapiens, the resulting strains are viable. By interchanging the fungal and mammalian capping machineries in yeast, it is possible to establish cell-based screening assays to identify small molecules that inhibit the growth of strains that express the C. albicans CaCET1, CGT1, and CCM1 enzymes while having little or no effect on congenic strains that express the mammalian MCE1 and HCM1 enzymes.
In this article, we describe the development of several cellbased assays to identify fungal-specific inhibitors of mRNA capping using the yeast strains developed by Shuman and colleagues. 8, 20 We used these assays to screen different chemical collections, as well as to identify and characterize compounds with properties expected from an inhibitor of mRNA capping. One set of assays monitors growth inhibition, whereas the second set measures inhibition of an inducible reporter gene. The growth inhibition assay was developed in a 96-well format and has been used to screen a collection of antifungal compounds over a 1000-fold range of concentrations. In this assay, 4 compounds exhibited~5-to 10-fold specificity toward the strains expressing the C. albicans or yeast mRNA capping genes. One of the compounds identified in the growth inhibition assay is sinefungin, a natural product antifungal agent that is structurally related to AdoMet. 21, 22 We also developed a rapid 96-well reporter gene assay using the LacZ gene and a sensitive luminescent substrate. The reporter assay was used to characterize compounds identified in the growth inhibition assay and screen a collection of~550 pure natural products. In the reporter assay, sinefungin also exhibited specificity toward strains expressing the yeast or fungal mRNA capping genes. It was also identified as a fungal specific inhibitor in our screen of natural products. We also used the growth inhibition and reporter gene assays with yeast strains expressing the C. albicans CCM1 or mammalian HCM1 cap methyltransferases to provide genetic evidence that sinefungin differentially inhibits yeast growth in our assays by inhibiting cap methyltransferases. Our findings that sinefungin inhibits the fungal and human cap methyltransferases are supported by observations that this natural product also inhibits the methylation of RNAs catalyzed by viral 23, 24 and parasitic 25 AdoMetdependent transmethylases.
MATERIALS AND METHODS

Yeast strains
Many of the S. cerevisiae strains used in this study were provided by Stewart Shuman (Memorial Sloan-Kettering) ( Table 1) . These isogenic haploid strains are derived from strain W303 (Rodney J. Rothstein, Columbia University). Strains YSC1733, YSC1734, and YSC1735 are deleted at the 3 essential chromosomal genes encoding components of the yeast mRNA capping apparatus and are complemented by plasmid copies of the genes from S. cerevisiae, C. albicans, or human, respectively. Strains YSC1738 and YSC1739 are abd1 null mutants lacking the (guanine-7)-methyltransferase gene and complemented by either a plasmid copy of the C. albicans (CCM1) or human (guanine-7)- Strains YSC1733, YSC1734, YSC1735, YSC1738, and YSC1739 were transformed with plasmid pYC33/171/252/LacZ containing a tetracycline-inducible lacZ reporter gene by the method of Elble. 26 The transformants were named YSC1768, YSC1770, YSC1772, YSC1809, and YSC1810, respectively.
Plasmids
pYC33/171/252/LacZ contains the URA3 gene, the reverse tTA, and the TET02 operator upstream of the LacZ gene and was constructed from plasmids pCM171 and pCM252 27 in 3 steps. An oligonucleotide linker (AAGCTTGCAGATCTGCAAGCTT) containing a BglII site was inserted into the HindIII site of pCM171. An EcoRI-NcoI DNA fragment containing the reverse tTA, the TET02 operator, and the LacZ gene from pCM252 was subcloned into the EcoRI and NcoI sites of the modified pCM171 vector to yield pCM171/252. Last, an EcoRI-BglII DNA fragment from pCM171/252 containing the reverse tTA, the TET02 operator, and the LacZ gene was cloned into EcoRI and BamHI sites of the URA3 shuttle vector YCplac33. 28
Media and reagents
Basic medium contained per liter the following: 20 g of D-(+)glucose, 6.7 g of yeast nitrogen base without amino acids (Difco 0919-15), 1 g of Casamino acids (Difco 0231-17-2), 40 mg of adenine, and 20 mg uracil. After adjusting the pH to 5.8 with KOH, the medium was filter sterilized through a sterile 0.22-µm cellulose acetate filter (Corning Life Sciences, Acton, MA) and stored at 4°C. Strains containing the reporter plasmid were grown in Basic medium lacking uracil. Sinefungin (Sigma S-8559) stock solutions were prepared in DMSO. Doxycycline (Sigma D-9891) stock solutions of 10 mg/mL were made in ethanol. The Gal-Screen Reagent (Tropix GSC010) and Buffer B (Tropix ABGS020Y) mixture, which combines direct cell lysis with chemiluminescent detection of the β-galactosidase reporter enzyme, was prepared according to the manufacturer's directions and used within 15 min.
Antifungal susceptibility studies
Strains YSC1733, YSC1734, and YSC1735 were inoculated into 50 mL Basic medium with uracil in 250 mL beveled Bellco flasks from frozen aliquots (25 µL at OD 660 = 1.68, 25 µL at OD 660 = 1.91, and 200 µL at OD 660 = 5.70, respectively). The cultures were incubated at 28°C for 21 to 24 h to a similar final cell density in stationary phase (0.5-1.0 × 10 8 cells/mL). The cultures were diluted into fresh Basic medium with uracil to an OD 660 = 0.01. Aliquots of 198 µL were dispensed to each well of a 96-well microplate, and 2 µL of test compound (1% DMSO final) was added to each well. A no-compound control containing 2 µL of DMSO and a media blank control were added to each plate. The microplates were shaken (DPC Micromix 5 set at form 20 and intensity 7) for 1 min before and after incubation. Incubation times for the fungal and mammalian strains were adjusted (21 and 26 h at 28°C, respectively) to give approximately equivalent cell densities for the no-compound controls. Plates were read spectrophotometrically at 620 nm with a plate reader (Tecan Spectrafluor Plus).
Reporter gene assay
Strains YSC1768, YSC1770, and YSC1772 were inoculated into 50 mL Basic medium in 200-mL Erlenmeyer flasks from frozen aliquots (250 µL at OD 600 = 0.09-1.1) and incubated at 250 rpm and 30°C for 18 to 24 h. The final cell density of OD 600 = 0.8-2.75 was adjusted with fresh Basic medium to an OD 600 = 0.025. To each well of an assay plate (Packard 96-well Opti-Plate 6005190), 88 µL of diluted cells, 2 µL of test compound, and 10 µL of Basic medium with doxycycline (20 µg/mL) were dispensed. After the plates were incubated without shaking at 30°C for 4 h, 100 µL of room temperature Gal-Screen Reagent in Buffer B (4 µL of Gal-Screen Reagent in 96 µL of Buffer B) was added. The resultant mixture was incubated without shaking at room temperature for 1 h. Plates were read for luminescence in a Packard TopCount (1 sec/ well, 5-min delay).
Antifungal agents and natural product samples
Thirty-six antifungal compounds with diverse modes of action were tested in the antifungal susceptibility test. The compounds were assayed at four 10-fold serial dilutions to evaluate the compounds at approximately MIC, sub-MIC, and noninhibitory concentrations. The final DMSO concentration was 1% for each compound. The following compounds were tested with the highest concentration (in µg/mL) noted in parentheses: aculeacin (16) , amphotericin (100), anisomycin (50), aphidicolin (100), 25azacholesterol (5), calcofluor white (10), L-canavanine (100), cerulenin (3), cetyltrimethylammonium bromide (10), cycloheximide (1), cyclosporine A (500), enfumafungin (2), filipin (100), fluconazole (300), flucytosine (100), hydroxyurea (100), hygromycin (300), juglone (100), ketoconazole (75), lunatoic acid A (100), mevinolinic acid sodium salt (50), monensin (50), nigericin (20) , nystatin (100), pneumocandin B 0 (50), rapamycin (2.5), sinefungin (1), sphingofungin B (10), staurosporine (10), terbinafine (20) , trifluoperazine (70), trichostatin (100), sodium vanadate (250), viridiofungin A (100), wortmannin (100), and zaragozic acid (50) . A random selection of samples from our natural products collection was provided by Dr. Robert Schwartz and Dr. Michael Goetz (Merck Research Laboratories, Rahway, NJ) and screened in the reporter gene assay at a final concentration of 0.2 mg/mL.
RESULTS
Development of a growth inhibition assay with yeast strains expressing mRNA capping genes
To establish a cell-based growth inhibition assay to screen for fungal-specific inhibitors of mRNA capping, we developed growth conditions in a 96-well plate for yeast strains expressing the S. cerevisiae, C. albicans, or mammalian mRNA capping genes, as well as a simple data acquisition and analysis system managed with Microsoft Excel. The strains are deleted at the 3 essential chromosomal genes encoding components of the yeast mRNA capping apparatus and are complemented by plasmid copies of the S. cerevisiae, C. albicans, or human genes. Cells were grown for 21 to 24 h, and optical densities were read in a Spectrafluor plate reader. Under the conditions used in this assay, the growth rates of the strains expressing the S. cerevisiae, C. albicans, or human mRNA capping genes were 2.2, 2.2, and 3.3 h (data not shown), respectively. Using the assay and data analysis system, we examined the antifungal sensitivities of strains YSC1733, YSC1734, and YSC1735 to a panel of 37 antifungal compounds with diverse modes of action. Although most of the compounds exhibited similar antifungal activities against each of these strains (data not shown), the strains expressing either the S. cerevisiae (YSC1733) or C. albicans (YSC1734) capping mRNA genes were approximately 5-fold more sensitive to the methyltransferase inhibitor sinefungin, the serine palmitoyltransferase inhibitor sphingofungin B, the fatty acid synthesis inhibitor cerulenin, and the energy and membrane perturbant nigericin than was the congenic strain expressing the human (YSC1735) mRNA capping genes. The sensitivities of the 3 strains to sinefungin in a typical assay are illustrated in Figure 1B . The average IC 50 s (6 experiments) for this compound against strains YSC1733, YSC1734, and YSC1735 were 0.0223, 0.0232, and 0.1122 µg/ mL, respectively.
Development of an inducible reporter gene assay to detect fungal-specific mRNA capping inhibitors
Because mRNA capping is essential for the stability and translation of eukaryotic mRNAs, we developed an inducible reporter gene assay that could be used to identify potential inhibitors of mRNA capping and evaluate their cellular properties. A plasmid containing a doxycycline-inducible lacZ reporter gene was transformed into the yeast strains expressing the yeast, C. albicans, or mammalian mRNA capping genes to generate strains YSC1768, YSC1770, and YSC1772, respectively. Strains expressing the yeast or fungal mRNA capping genes expressed a basal level of βgalactosidase that increased 10-fold after 4 h in the presence of doxycycline ( Fig. 2A) . The basal level of lacZ activity in the reporter strain expressing the human mRNA capping genes is~10to 20-fold lower than that seen in the strains expressing the fungal mRNA capping genes. However, when this strain was grown in the presence of doxycycline, lacZ expression was also induced 10fold compared to noninduced cells. To validate the assay, cycloheximide and anisomycin were assayed to confirm that reporter gene induction was dependent on newly translated RNA (data not shown).
When sinefungin, sphingofungin B, cerulenin, and nigericin were tested in the reporter gene assay, sinefungin was the only compound that inhibited β-galactosidase activity in a dose-dependent manner (data not shown). Moreover, sinefungin was~10 to 15 times more potent an inhibitor of the strains expressing the yeast or fungal mRNA capping genes (YSC1768 and YSC770) when compared to the strain expressing the human mRNA capping genes (YSC1772) (Fig. 2B) . The IC 50 s for sinefungin were 0.013, 0.015, and 0.293 µg/mL for YSC1768, YSC1770, and YSC1772, respectively. Sphingofungin B, cerulenin, and nigericin were inactive in the reporter gene assay (data not shown), and they were not pursued further.
The performance of an assay can be evaluated by the Z′ factor, a statistical coefficient that demonstrates the potential of an assay to identify compounds of interest. 29 Values that exceed 0.5 but are less than the maximum of 1.0 indicate that the assay has little variability in the both the sample and control data and that a large sepa- ration exists between them. The reporter assay demonstrated a Z′ factor of 0.72 when tested with control samples from our natural products collection, indicating that the assay was robust and should be capable of identifying compounds of interest (Fig. 2C ). We identified 155 unknown natural product mixtures that exhibited greater than 90% inhibition (data not shown). A collection of 550 pure natural products were also screened in the reporter as-say. In our survey of pure compounds, sinefungin was also independently identified as an inhibitor with fungal specificity.
Development of secondary assays using hybrid strains expressing cap methyltransferases
AdoMet and sinefungin have similar chemical structures (Fig.  1A) , and sinefungin is a known inhibitor of methyltransferases. 30 
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We hypothesized that strains that express fungal mRNA capping genes are more sensitive to sinefungin than the strain expressing the human capping genes because the compound is a more potent inhibitor of the fungal cap methyltransferases. To test this, we developed cell-based growth and reporter assays using yeast abd1∆ strains YSC1738 and YSC1739 expressing the C. albicans Ccm1 or human Hcm1 methyltransferases, respectively. When antifungal susceptibility tests were performed with these strains, sinefungin was a more potent inhibitor of the growth of strains expressing the fungal cap methyltransferases than of the strain expressing the human methyltransferase ( Fig. 3 ). Strain YSC1738, as well as YSC1734, which contains the 3 C. albicans mRNA capping genes, demonstrated similar sensitivities (IC 50 = 0.006 and 0.008 µg/mL, respectively). Strain YSC1739, which expresses the human Hcm1 enzyme, is less susceptible to sinefungin (IC 50 = 0.047 µg/mL) than strains YSC1734 and YSC1738. The reduced sinefungin sensitivity of YSC1739 is similar to that of strain YSC1735 (IC 50 = 0.044 µg/mL), which expresses the human RNA triphosphatase, guanyl transferase, and cap methyltransferase. We also developed a reporter gene assay with strains expressing either the C. albicans or human cap methyltransferase genes. Strains expressing the C. albicans (YSC1738) or human (YSC1739) cap methyltransferase genes were transformed with the reporter plasmid, and the resulting transformants were analyzed in the reporter assay with sinefungin ( Fig. 4) . In this assay, the strain expressing the C. albicans Ccm1 enzyme (YSC1809, IC 50 = 0.022 µg/mL) was approximately 7-fold more sensitive to sinefungin than was the strain expressing Hcm1 (YSC1810, IC 50 = 0.164 µg/mL). The sensitivity of YSC1809 was similar to that of the strains containing the fungal mRNA capping genes, and the sensitivity of YSC1810 was similar to that of the strain expressing the 3 human mRNA capping genes.
DISCUSSION
In an effort to discover inhibitors of fungal mRNA capping, we developed 2 cell-based assays using yeast strains expressing fungal or mammalian mRNA capping genes. Both assays can be run in 96-well microplate formats. The assays are designed to measure inhibition of growth or inhibition of a doxycycline-inducible reporter gene. Because mRNA capping is essential for growth of S. cerevisiae, the growth inhibition assay allows compounds to be screened against several strains at different concentrations. In the assay, optical density is used to measure growth, which can be read quickly and repeatedly over the course of the assay. Most important, the assay measures the antifungal properties of potential inhibitors directly. The primary limitation of an antifungal susceptibility assay in this format is the incubation time of the assay, which is affected by strains with different growth rates, as well as the difficulty in screening compounds over the wide concentration ranges that can be monitored with a single sample in disc diffusion assays on agar-based growth media. Although the growth rate of the yeast strain expressing the human mRNA capping genes is 1.5fold slower than that of the strains expressing the S. cerevisiae or C. albicans genes, most of the compounds tested exhibit similar potencies against the 3 yeast strains, indicating that this change in growth rate does not affect susceptibility to most compounds with antifungal activity. The reporter gene assay described in this article offers advantages of a much shorter incubation time with test compounds (~4 h) and a highly sensitive luminescent read-out, which can also be run in a 1536-well format (data not shown). Another important advantage of the reporter assay is the potential to detect compounds that inhibit reporter gene expression at concentrations below those required to inhibit growth. We used the growth inhibition and reporter gene assays to screen different chemical collections and characterize actives in each. Our independent identification of sinefungin in both assays, as well as our characterization and prioritization of this active, is a good example of the utility of both screens. In the growth inhibition screen of antifungal agents, most compounds exhibit similar potencies against yeast strains expressing mRNA capping genes from S. cerevisiae, C. albicans, or mammalian cells. However, 4 compounds in a small antifungal collection (sinefungin, sphingofungin B, cerulenin, and nigericin) are~5-fold more potent growth inhibitors of cells expressing the yeast or C. albicans mRNA capping genes.
The tetracycline-inducible reporter gene assay described in this article was useful in evaluating the properties of sinefungin, sphingofungin B, cerulenin, and nigericin and identifying a compound(s) that has characteristics expected from an mRNA capping inhibitor. The reporter strains expressing the S. cerevisiae, C. albicans, or mammalian capping genes express a basal level of βgalactosidase activity that is induced 10-fold by doxycycline in a time-dependent manner. In this assay, sinefungin is~10-fold more inhibitory against the strains expressing the fungal mRNA capping genes than it is against the congenic strain expressing the mammalian genes. Sphingofungin B, cerulenin, and nigericin do not demonstrate significant dose-dependent inhibition when tested in the reporter assay and were not characterized further.
Sinefungin is structurally related to AdoMet and can act as a competitive inhibitor of AdoMet-dependent enzymatic reactions. Because the final posttranscriptional step in mRNA cap formation is catalyzed by an RNA (guanine-N7)-methyltransferase, we postulated that sinefungin is active in our screens because it inhibits fungal and, to a lesser degree, mammalian RNA (guanine-N7)methyltransferases. Our hypothesis is supported by our findings that this natural product exhibits the expected activity profile in the growth inhibition and reporter gene assays. Strains expressing the C. albicans CCM1 gene (RNA (guanine-N7)-methyltransferase) or the 3 heterologous C. albicans mRNA capping genes (CCM1/ CET1/CGT1) exhibit similar sensitivities to sinefungin in both assays. Similarly, strains expressing the mammalian mRNA capping genes (HCM1/MCE1) or the HCM1 and S. cerevisiae CET1 and CEG1 genes exhibit reduced sensitivities to sinefungin. On the basis of these findings, we conclude that this natural product inhibits fungal and mammalian mRNA (guanine-7)-methyltransferases and that it is~5-to 10-fold more potent against the fungal methyltransferases Abd1 and Ccm1. Our conclusions are supported by the findings of Pugh and colleagues 23, 24 and McNally and Agabian, 25 who demonstrated that sinefungin inhibits the AdoMet-dependent transmethylations catalyzed by the vaccinia virion mRNA (guanine-7)-and (nucleoside-2′-O)-methyltransferases, as well as the RNA methylations of Trypanosoma brucei spliced-leader RNAs that contain a m7G cap.
In screens for fungal mRNA capping inhibitors, we discovered that sinefungin, an AdoMet analog that inhibits methyltransferase activity, was more potent as an inhibitor of fungal cap methyltransferase. Because the fungal and mammalian methyltransferases use similar catalytic mechanisms, we compared their sequences in detail to determine whether there might be key differences in their active sites. Although the sequence similarities between the DNA, RNA, and glycine N-methyltransferases (GNMT) are very low, crystal structures of the AdoMet binding sites of several of these enzymes reveal a common fold of a mixed β-sheet structure called the AdoMet-dependent MTase fold. 31 Structure-guided sequence comparisons of these methyltransferases also reveal 9 conserved motifs (I-VIII and X), 5 of which (motifs I-IV and X) may be involved in AdoMet binding. 32, 33 The sequence of the yeast Abd1 cap methyltransferase has also been analyzed computationally, 34 is most similar to GNMT, 35 and contains these conserved motifs in its primary sequence. The AdoMet binding motifs are also conserved in Abd1, Ccm1, and Hcm1 (Fig. 5) . Overall, the yeast and C. albicans enzymes share 39% identity and 52% similarity and are more distantly related to Hcm1, with which they share~22% identity and~38% similarity. Mutational analyses of the S. cerevisiae Abd1, C. albicans Ccm1, and human Hcm1 cap methyltransferases have identified several amino acid residues located within the motifs I-VI and X that are essential for catalysis and are conserved among cap methyltransferases (Fig. 5 ). 8, 34, [36] [37] [38] [39] [40] Many of these mutations are lethal or severely impair cell growth. We examined the conserved motifs within the AdoMet binding sites for amino acid residues that might contribute to the fungal specificity we observe in our experiments. Several nonconserved amino acids are present in motifs II, III, IV, and X of the fungal and human (guanine-7)-methyltransferases ( Fig. 5 ). Mutagenesis studies of these residues in the fungal and mammalian enzymes might provide new insight into how AdoMet and sinefungin interact with these substrate binding sites.
Although the genes encoding components of the mRNA capping machinery are essential in S. cerevisiae, the role that mRNA capping plays in the pathogenic fungus C. albicans is unclear. Pei et al. 10 reported that the C. albicans CET1 gene encoding the RNA 5′ triphosphatase is essential because they were unable to generate a homozygous null mutant in this diploid organism using the single-step method of Enloe et al. 41 In contrast, Dunyak et al. 42 demonstrated that homozygous null mutations can be introduced into the C. albicans CET1 or CCM1 genes by the 2-step transformation procedure of Wilson et al. 43 and that the resulting mutants are viable. This group also found no evidence for redundant genes or alternative mRNA capping pathways in C. albicans. The CGT1 gene is required for growth in vitro. 42 Dunyak et al. 42 propose that C. albicans null mutants survive because the mRNAs contain modified cap structures that can be detected in vivo. It is worth noting that viable C. albicans CET1/CET1 and CCM1/CCM1 null mu-Assays to Detect Inhibitors of Fungal mRNA Capping Enzymes tants are temperature sensitive or show impaired growth rates, suggesting that mRNA capping may still be an attractive target for the development of antifungal drugs to treat C. albicans infections.
AdoMet is an essential organic molecule used by 3 important cellular reactions (transmethylation, transsulfuration, and polyamine synthesis) in many metabolic processes. 32 Because sinefungin inhibits many AdoMet-dependent methylation reactions, the specific mechanism(s) by which this natural product inhibits growth of yeast and fungi is unclear. Sinefungin arrests yeast cells at the start in the G1 phase of the cell cycle 44, 45 and inhibits sterol methylation, methylation of rRNAs, and the stability of 18S rRNA in S. cerevisiae. 46, 47 We observe that sinefungin inhibits yeast growth at concentrations that have been reported to rapidly arrest the yeast cell cycle and inhibit fungal growth. 21, 45, 46 Sinefungin inhibits growth of C. albicans at concentrations of~1.6 to 3.2 µg/mL in defined medium, 21 but it exhibits weak activity against isolates of C. tropicalis, C. parapsilosis, and C. quillliermondii. The natural product also inhibits growth of Cryptococcus neoformans, Blastomyces dermatitidis, and Histoplasma capsulatum in vitro at MICs ranging from 25 to 100 µg/mL, 21 as well as Ceratostomella ulmi, Helminthosporium sativum, and Penicillium expansum. 22 On the basis of our findings, we propose that this natural product inhibits yeast and fungal growth in part by inhibiting mRNA capping. The activity of sinefungin should be examined against other isolates of pathogenic fungi.
Sinefungin also exhibits antifungal activity against C. albicans in mice when administered subcutaneously twice daily for 3 days. 21 In this study, the compound extends average survival time by 50% to 128% at doses of 1.25 to 10 mg/kg and reduces the number of viable C. albicans in kidney homogenates. Intraperitoneal and oral administration of sinefungin are also effective in treating mice infected with C. albicans, although oral administration is less effective. 21 In the same study, 40-to 50-mg/kg total doses of sinefungin were inactive against mice infected with C. neoformans, B. dermatitidis and H. capsulatum. Several studies of sinefungin as an antiprotozoal agent have been conducted in animal models at a range of doses. In murine and rat immunodeficient models, it exhibits anticryptosporidial activity when administered orally at doses up 10 mg/kg for 10 days with no overt signs of toxicity. [48] [49] [50] It is also efficacious as a trypanocidal agent in mice against some T. brucei stocks. 51 Toxicity has been observed in hamsters and goats administered sinefungin intramuscularly. , and human (HCM1). The ABD1, CCM1, and HCM1 proteins were aligned in ClustalW version 1.8 and viewed in GeneDoc version 2.6.002. Identical and conserved residues are shaded black or gray, respectively. Conserved motifs in the AdoMet binding site are indicated with lines beneath the sequence alignment. Arrows indicate amino acid residues required for catalytic activity. Double lines above amino acid residues indicate regions that are conserved within motifs II to IV and X in the yeast ABD1 and C. albicans CCM1 cap methyltransferases but divergent in the human HCM1 enzyme.
Twice-daily intramuscular administration in hamsters at doses of 26, 104, and 208 mg/kg leads to slightly roughened hair coats, indicating possible toxicity. 52 In goats, single intramuscular administration at doses of 25 to 50 mg/kg causes death, 53 whereas single doses of 10 to 20 mg/kg did not cure Trypanosoma (Nannomonas) congolense infection. The experiments described in this article indicate that sinefungin is an inhibitor of mRNA cap methyltransferases with some specificity for fungal and yeast enzymes. The whole-cell assays described in this article can be used to support the identification and development of fungal-specific cap methyltransferase inhibitors.
